Evidence map›Paper›PMID 39448366›Full record

ArticleACS applied materials & interfaces2024

Drug-Free Mesoporous Silica Nanoparticles Enable Suppression of Cancer Metastasis and Confer Survival Advantages to Mice with Tumor Xenografts.

Yu-Tse Lee, Si-Han Wu, Cheng-Hsun Wu, Yu-Han Lin, Cong-Kai Lin, Zih-An Chen, Ting-Chung Sun, Yin-Ju Chen, Peilin Chen, Chung-Yuan Mou and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu-Tse LeeDepartment of Chemistry, National Taiwan University, Taipei 10617, Taiwan.
Si-Han WuGraduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-2586-7538
Cheng-Hsun WuNano Targeting & Therapy Biopharma Inc., Taipei 10087, Taiwan.
Yu-Han LinGraduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
Cong-Kai LinGraduate Institute of Biomedical Materials & Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
Zih-An ChenGraduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
Ting-Chung SunNano Targeting & Therapy Biopharma Inc., Taipei 10087, Taiwan.
Yin-Ju ChenGraduate Institute of Biomedical Materials & Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
Peilin ChenResearch Center for Applied Sciences, Academia Sinica, Taipei 11529, Taiwan.ORCID 0000-0003-4154-0487
Chung-Yuan MouDepartment of Chemistry, National Taiwan University, Taipei 10617, Taiwan.ORCID 0000-0001-7060-9899
Yi-Ping ChenGraduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0001-5443-2632

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advancements in nanomedicine for drug delivery, many drug-loaded nanoparticles reduce tumor sizes but often fail to prevent metastasis. Mesoporous silica nanoparticles (MSNs) have attracted attention as promising nanocarriers. Here, we demonstrated that MSN-PEG/TA 25, with proper surface modifications, exhibited unique antimetastatic properties. In vivo studies showed that overall tumor metastasis decreased in 4T1 xenografts mice treated with MSN-PEG/TA 25 with a notable reduction in lung tumor metastasis. In vitro assays, including wound-healing, Boyden chamber, tube-formation, and real-time cell analyses, showed that MSN-PEG/TA 25 could modulate cell migration of 4T1 breast cancer cells and interrupt tube formation by human umbilical vein endothelial cells (HUVECs), key factors in suppressing cancer metastasis. The synergistic effect of MSN-PEG/TA 25 combined with liposomal-encapsulated doxorubicin (Lipo-Dox) significantly boosted mouse survival rates, outperforming Lipo-Dox monotherapy. We attributed the improved survival to the antimetastatic capabilities of MSN-PEG/TA 25. Moreover, Dox-loaded MSN-PEG/TA 25 suppressed primary tumors while retaining the antimetastatic effect, thereby enhancing therapeutic outcomes and overall survival. Western blot and qPCR analyses revealed that MSN-PEG/TA 25 interfered with the phosphorylation of ERK, FAK, and paxillin, thus impacting focal adhesion turnover and inhibiting cell motility. Our findings suggest that drug-free MSN-PEG/TA 25 is highly efficient for cancer treatment via suppressing metastatic activity and angiogenesis.

Indexed as

DoxorubicinHuman Umbilical Vein Endothelial CellsNanoparticlesSilicon DioxideAnimalsBreast NeoplasmsCell Line, TumorCell MovementDrug CarriersFemaleHumansLung NeoplasmsMiceMice, Inbred BALB CNeoplasm MetastasisPolyethylene GlycolsDoxorubicinDrug Carriersliposomal doxorubicinPolyethylene GlycolsSilicon Dioxideangiogenesiscell motilityfocal adhesion turnovermesoporous silica nanoparticles (MSNs)metastasis

Identifiers

PMID39448366
PMCPMC11565475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.